GENMAB A/S

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1059, GEN1055, and GEN1057 for solid tumors; and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Medarex, Inc., Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Novo Nordisk A/S, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.

덴마크에 본사를 둔 생명공학 기업 Genmab A/S는 암 및 기타 질병 치료를 위한 항체 기반 제품 및 후보 물질을 개발합니다. 이 회사는 성인 재발성 또는 불응성(R/R) 미만성 거대 B세포 림프종(DLBCL), 거대 B세포 림프종, 여포성 림프종(FL) 환자를 위한 EPKINLY 및 TEPKINLY를, 그리고 화학요법 치료 중 또는 치료 후 질병이 진행된 성인 재발성/전이성 자궁경부암 환자를 위한 Tivdak을 시판하고 있습니다. 또한, Epcoritamab은 R/R DLBCL 및 FL, 1차 DLBCL 및 FL, B세포 비호지킨 림프종, R/R 만성 림프구성 백혈병 및 리히터 증후군, 소아 환자의 공격성 성숙 B세포 신생물 치료를 위해 개발 중이며, tisotumab vedotin은 고형암을, Acasunlimab은 고